
CYAD
Healthcare · Biotechnology & Medical Research · $14.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2015
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2023 | Time not confirmed | — | 0.00 | — |
| Sep 4, 2023 | Time not confirmed | -0.45 | 0.00 | +100.0% |
| May 5, 2023 | Time not confirmed | — | 0.00 | — |
| Mar 23, 2023 | Time not confirmed | -0.62 | 0.00 | +100.0% |
| Nov 10, 2022 | Time not confirmed | — | 0.00 | — |
| Aug 5, 2022 | Time not confirmed | -0.91 | -0.91 | 0.0% |
| May 5, 2022 | Time not confirmed | — | 0.00 | — |
| Mar 24, 2022 | Time not confirmed | -0.73 | -0.73 | 0.0% |
| Nov 10, 2021 | Time not confirmed | — | 1.49 | — |
| Aug 4, 2021 | Time not confirmed | -1.32 | -1.32 | 0.0% |
| May 6, 2021 | Time not confirmed | — | -0.49 | — |
| Mar 24, 2021 | After the close | -1.17 | -0.72 | +38.9% |
| Nov 10, 2020 | After the close | 0.00 | 0.00 | — |
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T…
| Aug 6, 2020 | After the close | -1.13 | -1.40 | -23.9% |
| May 7, 2020 | After the close | 0.00 | -0.67 | — |
| Mar 25, 2020 | Before the open | -1.30 | -0.66 | +49.5% |
| Nov 19, 2019 | Time not confirmed | — | 0.00 | — |
| Aug 27, 2019 | After the close | -1.73 | -1.96 | -13.3% |
| May 9, 2019 | Time not confirmed | — | 0.00 | — |
| Mar 29, 2019 | After the close | -1.78 | -1.91 | -7.3% |
| Nov 19, 2018 | Time not confirmed | — | 0.00 | — |
| Aug 23, 2018 | After the close | -1.91 | -2.06 | -7.9% |
| May 30, 2018 | Time not confirmed | — | 0.00 | — |
| Mar 22, 2018 | After the close | — | -5.23 | — |